🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Clinical Management and Outcomes of Primary Ovarian Leiomyosarcoma

Recruitingn/aAges 18 Years - 99 YearsFemaleAzienda USL Reggio Emilia - IRCCS
NCT06749600 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

This observational study aims to gather comprehensive data on primary ovarian leiomyosarcoma (POLMS). This extremely rare malignancy accounts for less than 3% of primary ovarian malignancies and has an incidence of only 1% among ovarian cancers. This national, retrospective and prospective multicenter study will collect and analyze historical cases of POLMS with remote diagnoses accessed through clinical case reviews and newly identified cases. The study aims to expand a previously identified series of 113 cases described in the literature, uncovering patterns in diagnosis, treatment, and outcomes and ultimately establishing evidence-based guidelines for the optimal management of this rare and aggressive cancer.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Diagnosis of primary leiomyosarcoma of the ovary; * Patients diagnosed with POLMS for whom data relating to diagnosis and treatment are available. * Aged between 18 and 99 years Exclusion Criteria: \- All patients with other forms of ovarian sarcoma (rhabdomyosarcomas, fibrosarcomas, stromal cell sarcomas) and patients diagnosed with leiomyosarcoma of the uterus will be excluded.
💊

What it tests

  • Not listed
📍

Where

10 sites
AOU Policlinico di Modena
Modena, Italy
Azienda Ospedaliero Universitaria di Parma - S.C. Ostetricia e Ginecologia
Parma, Italy
Azienda USL IRCCS di Reggio Emilia
Reggio Emilia, Italy
Malzoni - Avellino
Avellino, Italy
Azienda Ospedaliero Universitaria Policlinico "G.Rodolico - San Marco" - Catania
Catania, Italy
IRCCS Ospedale San Raffaele
Milan, Italy
Fondazione Irccs San Gerardo Dei Tintori
Monza, Italy
IRCCS Istituto Nazionale Tumori Fondazione Pascale
Naples, Italy

…and 2 more on ClinicalTrials.gov.

🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy